These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27183828)

  • 41. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
    Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
    Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy.
    van Gelder CM; van Capelle CI; Ebbink BJ; Moor-van Nugteren I; van den Hout JM; Hakkesteegt MM; van Doorn PA; de Coo IF; Reuser AJ; de Gier HH; van der Ploeg AT
    J Inherit Metab Dis; 2012 May; 35(3):505-11. PubMed ID: 22008944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients.
    Palermo AT; Palmer RE; So KS; Oba-Shinjo SM; Zhang M; Richards B; Madhiwalla ST; Finn PF; Hasegawa A; Ciociola KM; Pescatori M; McVie-Wylie AJ; Mattaliano RJ; Madden SL; Marie SK; Klinger KW; Pomponio RJ
    Mol Genet Metab; 2012 Jul; 106(3):287-300. PubMed ID: 22658377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells.
    Yoshida T; Jonouchi T; Osafune K; Takita J; Sakurai H
    Front Cell Dev Biol; 2019; 7():316. PubMed ID: 31850350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fasciculations in Late-Onset Pompe Disease: A Sign of Motor Neuron Involvement?
    Monforte M; Servidei S; Ricci E; Tasca G
    Can J Neurol Sci; 2017 Jul; 44(4):463-464. PubMed ID: 28143629
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low anal sphincter tone in infantile-onset Pompe Disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention.
    Tan QK; Cheah SM; Dearmey SM; Kishnani PS
    Mol Genet Metab; 2013 Feb; 108(2):142-4. PubMed ID: 23266370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
    Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
    Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series.
    Wang LY; Ross AK; Li JS; Dearmey SM; Mackey JF; Worden M; Corzo D; Morgan C; Kishnani PS
    Paediatr Anaesth; 2007 Aug; 17(8):738-48. PubMed ID: 17596219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI.
    Mogalle K; Perez-Rovira A; Ciet P; Wens SC; van Doorn PA; Tiddens HA; van der Ploeg AT; de Bruijne M
    PLoS One; 2016; 11(7):e0158912. PubMed ID: 27391236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pompe disease in infants: improving the prognosis by newborn screening and early treatment.
    Chien YH; Lee NC; Thurberg BL; Chiang SC; Zhang XK; Keutzer J; Huang AC; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
    Pediatrics; 2009 Dec; 124(6):e1116-25. PubMed ID: 19948615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A retrospective study of six patients with late-onset Pompe disease].
    Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
    Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density.
    van den Berg LE; Zandbergen AA; van Capelle CI; de Vries JM; Hop WC; van den Hout JM; Reuser AJ; Zillikens MC; van der Ploeg AT
    Bone; 2010 Sep; 47(3):643-9. PubMed ID: 20601298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
    Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G
    J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease.
    Schaaf GJ; van Gestel TJ; Brusse E; Verdijk RM; de Coo IF; van Doorn PA; van der Ploeg AT; Pijnappel WW
    Acta Neuropathol Commun; 2015 Oct; 3():65. PubMed ID: 26510925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.